Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul 15;104(4):705-709.
doi: 10.1016/j.ijrobp.2019.02.054.

De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?

Comment

De-Escalation Strategies in HPV-Associated Oropharynx Cancer-Are we Putting the Cart Before the Horse?

Carryn M Anderson et al. Int J Radiat Oncol Biol Phys. .
No abstract available

PubMed Disclaimer

Comment in

  • Cetuximab and Radiation Therapy in Head and Neck Cancer.
    Maddalo M, Triggiani L, Magrini SM Prof, Buglione M. Maddalo M, et al. Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):678-679. doi: 10.1016/j.ijrobp.2019.07.025. Int J Radiat Oncol Biol Phys. 2019. PMID: 31540600 No abstract available.

Comment on

Similar articles

Cited by

References

    1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363(1): 24–35. - PMC - PubMed
    1. Marur S, Li S, Cmelak AJ, et al. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol 2017; 35(5): 490–7. - PMC - PubMed
    1. Chen AM, Felix C, Wang PC, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. Lancet Oncol 2017; 18(6): 803–11. - PMC - PubMed
    1. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019; 393(10166): 40–50. - PMC - PubMed
    1. Mehanna H, Robinson M, Hartley A, et al.; De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019; 393(10166): 51–60. - PMC - PubMed

Publication types